Steven R. Schuster

1.1k total citations
24 papers, 549 citations indexed

About

Steven R. Schuster is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Steven R. Schuster has authored 24 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Hematology and 11 papers in Oncology. Recurrent topics in Steven R. Schuster's work include Multiple Myeloma Research and Treatments (14 papers), Protein Degradation and Inhibitors (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Steven R. Schuster is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Protein Degradation and Inhibitors (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Steven R. Schuster collaborates with scholars based in United States, Japan and United Kingdom. Steven R. Schuster's co-authors include Joseph Mıkhael, Rafaël Fonseca, A. Keith Stewart, P. Leif Bergsagel, Víctor H. Jiménez‐Zepeda, Nancy Bello, Craig B. Reeder, S. Vincent Rajkumar, Robert A. Kyle and Angela Dispenzieri and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Thoracic Oncology.

In The Last Decade

Steven R. Schuster

22 papers receiving 539 citations

Peers

Steven R. Schuster
Philip R. Greipp United States
David Lavergne France
Kazuya Tsuboi Japan
Yoshitaka Sunami Japan
Yoko Edahiro Japan
Mark Offer United Kingdom
DV Faller United States
Ashley A. Basiorka United States
Friederike Schneider Germany
Mark Juckett United States
Philip R. Greipp United States
Steven R. Schuster
Citations per year, relative to Steven R. Schuster Steven R. Schuster (= 1×) peers Philip R. Greipp

Countries citing papers authored by Steven R. Schuster

Since Specialization
Citations

This map shows the geographic impact of Steven R. Schuster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven R. Schuster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven R. Schuster more than expected).

Fields of papers citing papers by Steven R. Schuster

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven R. Schuster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven R. Schuster. The network helps show where Steven R. Schuster may publish in the future.

Co-authorship network of co-authors of Steven R. Schuster

This figure shows the co-authorship network connecting the top 25 collaborators of Steven R. Schuster. A scholar is included among the top collaborators of Steven R. Schuster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven R. Schuster. Steven R. Schuster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schuster, Steven R., et al.. (2024). Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32.. Journal of Clinical Oncology. 42(16_suppl). TPS7576–TPS7576. 1 indexed citations
2.
3.
Sborov, Douglas W., Charlotte Pawlyn, Tadao Ishida, et al.. (2024). Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.. Journal of Clinical Oncology. 42(16_suppl). 7522–7522. 1 indexed citations
4.
5.
Kessler, Elizabeth R., Eryn Callihan, Junxiao Hu, et al.. (2023). A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Research Communications. 3(6). 1004–1012. 3 indexed citations
6.
7.
Li, Chao, Lowell L. Hart, Taofeek K. Owonikoko, et al.. (2021). Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemotherapy and Pharmacology. 87(5). 689–700. 14 indexed citations
8.
Leach, Heather J., Amanda Wurz, Mackenzi Pergolotti, et al.. (2019). Exploring cardiologists’ and oncologists’ exercise recommendation and referral practices. Health Education Journal. 79(3). 266–276. 1 indexed citations
9.
Mahdi, Haider, Steven R. Schuster, David M. O’Malley, et al.. (2019). Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).. Journal of Clinical Oncology. 37(15_suppl). TPS5602–TPS5602. 10 indexed citations
10.
Hart, Lowell L., Patrick J. Roberts, Renata Ferrarotto, et al.. (2017). P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results. Journal of Thoracic Oncology. 12(1). S696–S696. 1 indexed citations
11.
Kortuem, K. Martin, Steven R. Schuster, Víctor H. Jiménez‐Zepeda, et al.. (2014). Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 14(4). 284–290.e5. 13 indexed citations
12.
Schuster, Steven R., K. Martin Kortuem, Yuan Xiao Zhu, et al.. (2013). The clinical significance of cereblon expression in multiple myeloma. Leukemia Research. 38(1). 23–28. 85 indexed citations
13.
Mıkhael, Joseph, Steven R. Schuster, Víctor H. Jiménez‐Zepeda, et al.. (2012). Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 119(19). 4391–4394. 269 indexed citations
14.
Schuster, Steven R., K. Martin Kortuem, Yuan Xiao Zhu, et al.. (2012). Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. Blood. 120(21). 194–194. 12 indexed citations
15.
Zhu, Yuan Xiao, Esteban Braggio, Jessica Schmidt, et al.. (2011). Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide. Blood. 118(21). 127–127. 14 indexed citations
16.
17.
Schuster, Steven R., S. Vincent Rajkumar, Angela Dispenzieri, et al.. (2010). IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. American Journal of Hematology. 85(11). 853–855. 56 indexed citations
18.
Schuster, Steven R., Brian L. Burnette, Giovanni De Petris, et al.. (2010). Paraneoplastic polymyositis associated with mesothelioma: a brief report. Community Oncology. 7(4). 178–180.
19.
Schuster, Steven R., et al.. (2006). Relationship Between the Cardiometabolic Syndrome and Obstructive Sleep Apnea. PubMed. 1(3). 204–208. 14 indexed citations
20.
Draube, Andreas, Ronald R. Pfister, Martina Vockerodt, et al.. (2001). Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Annals of Hematology. 80(2). 83–89. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philip R. Greipp Breakdown of academic impact, for papers by David Lavergne Breakdown of academic impact, for papers by Kazuya Tsuboi Breakdown of academic impact, for papers by Yoshitaka Sunami Breakdown of academic impact, for papers by Yoko Edahiro Breakdown of academic impact, for papers by Mark Offer Breakdown of academic impact, for papers by DV Faller Breakdown of academic impact, for papers by Ashley A. Basiorka Breakdown of academic impact, for papers by Friederike Schneider Breakdown of academic impact, for papers by Mark Juckett
Rankless by CCL
2026